The American Cancer Society and St. Baldrick’s Foundation recently awarded $1.2 million in a second round of Pilot Accelerator grants requiring researchers to use clinical trials to accelerate treatment options for childhood cancer.
The American Society for Transplantation and Cellular Therapy presented awards to researchers in the field of transplantation and cellular therapy at the tandem meetings of ASTCT and the Center for International Blood and Marrow Transplant Research.
Independence Blue Cross and the Colorectal Cancer Alliance announced a cancer screening and prevention program which aims to address the decrease in colorectal cancer screening rates among Black Philadelphians since the pandemic started.
Stand Up To Cancer appointed five new members to the SU2C Health Equity Committee. SU2C established the Health Equity Committee in 2018, a year after it began developing its Health Equity Initiative. The initiative was formally announced in 2020.
The phase II COAST clinical trial demonstrated improved outcomes using immunotherapy combinations for patients with unresectable stage III non-small cell lung cancer, according to researchers at Yale Cancer Center, Cancer Center of Kansas, University of Colorado, Abramson Cancer Center, Astrazenaca, and collaborating international organizations.
The American Society of Clinical Oncology published an update expanding the utility of Breast Cancer Index, developed by Hologic Inc., within its Clinical Practice Guideline, “Biomarkers for Adjuvant Endocrine and Chemotherapy in Early-Stage Breast Cancer.”
The Committee for Medicinal Products for Human Use of the European Medicines Agency adopted a positive opinion and recommended granting marketing authorization for Tabrecta (capmatinib) as a monotherapy for the treatment of adults with advanced non-small cell lung cancer harboring alterations leading to mesenchymal-epithelial-transition factor gene exon 14 (METex14) skipping who require systemic therapy following prior treatment with immunotherapy and/or platinum-based chemotherapy.
Portage Biotech Inc., NCI, and Stimunity entered a Cooperative Research and Development Agreement, under which they will collaborate with NCI’s Center for Cancer Research to advance preclinical and potential clinical development of STING agonists and anti-Receptor for Advanced Glycation End products (RAGE) agents to enhance the efficacy of cancer vaccines developed in the NCI CCR Vaccine Branch.
FDA granted clearance to version 1.1 of the next generation SmartFrame Array Neuro Navigation System and Software, sponsored by ClearPoint Neuro Inc.
William L. Dahut, the NCI clinical director, was named chief scientific officer of the American Cancer Society.
